验证妊娠期低剂量CT肺动脉造影的安全性:OPTICA(妊娠期优化CT肺动脉造影)研究结果
OPTICA为前瞻性观察研究,2018年5月至2022年2月对113例疑似肺栓塞孕妇行同一低剂量CT肺动脉造影方案。阴性者随访3个月复发性症状性静脉血栓栓塞发生率为0.0%(单侧95%CI 2.66%),平均乳腺吸收剂量2.9±2.1mGy、胎儿剂量0.1±0.2mGy、母体有效剂量1.4±0.9mSv。
要点
- 低剂量CTPA阴性后3个月复发性症状性VTE发生率为0.0%(单侧95%CI 2.66%)。
- 平均乳腺吸收剂量2.9±2.1mGy、子宫/胎儿剂量0.1±0.2mGy、母体有效剂量1.4±0.9mSv。
- 图像质量:信噪比11.9±3.7,对比噪声比10.4±3.5。
核心结论
- OPTICA低剂量CTPA方案可在各孕期安全排除肺栓塞,胎儿与母体辐射剂量低。
研究设计与样本
- 前瞻性观察研究(OPTICA,NCT04179487),2018年5月至2022年2月纳入疑似肺栓塞孕妇,共行116次CTPA(113例孕妇),排除16次CTPA。
诊断标准与关键数值
- 主要结局CTPA安全性以参考标准判定,即指数CTPA阴性者3个月静脉血栓栓塞发生率为0.0%(单侧95%CI 2.66%);116次CTPA中诊断肺栓塞1次、排除99次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Pulmonary embolism (PE) is a leading cause of pregnancy-related mortality. CT pulmonary angiogram (CTPA) is the first-line advanced imaging modality for suspected PE in pregnancy at institutes offering low-dose techniques; however, a protocol balancing safety with low dose remains undefined. The wide range of CTPA doses reported in pregnancy suggests a lack of confidence in implementing low-dose techniques in this group.
PURPOSE: To define and validate the safety, radiation dose and image quality of a low-dose CTPA protocol optimised for pregnancy.
MATERIALS AND METHODS: The OPTICA study is a prospective observational study. Pregnant study participants with suspected PE underwent the same CTPA protocol between May 2018 and February 2022. The primary outcome, CTPA safety, was judged by the reference standard; the 3-month incidence of venous thromboembolism (VTE) in study participants with a negative index CTPA. Secondary outcomes defined radiation dose and image quality. Absorbed breast, maternal effective and fetal doses were estimated by Monte-Carlo simulation on gestation-matched phantoms. Image quality was assessed by signal-to-noise and contrast-to-noise ratios and a Likert score for pulmonary arterial enhancement.
RESULTS: A total of 116 CTPAs were performed in 113 pregnant women of which 16 CTPAs were excluded. PE was diagnosed on 1 CTPA and out-ruled in 99. The incidence of recurrent symptomatic VTE was 0.0% (one-sided 95% CI, 2.66%) at follow-up. The mean absorbed breast dose was 2.9 ± 2.1mGy, uterine/fetal dose was 0.1 ± 0.2mGy and maternal effective dose was 1.4 ± 0.9mSv. Signal-to-noise ratio (SNR) was 11.9 ± 3.7. Contrast-to-noise ratio (CNR) was 10.4 ± 3.5.
CONCLUSION: The OPTICA CTPA protocol safely excluded PE in pregnant women across all trimesters, with low fetal and maternal radiation.
CLINICAL RELEVANCE: OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) is the first prospective study to define the achievable radiation dose, image-quality and safety of a low-dose CT pulmonary angiogram protocol optimised for pregnancy (NCT04179487). It provides the current benchmark for safe and achievable CT pulmonary angiogram doses in the pregnant population.
KEY POINTS: • Despite the increased use of CT pulmonary angiogram in pregnancy, an optimised low-dose protocol has not been defined and reported doses in pregnancy continue to vary widely. • The OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) study prospectively defines the achievable dose, image quality and safety of a low-dose CT pulmonary angiogram protocol using widely available technology. • OPTICA provides a benchmark for safe and achievable CT pulmonary angiogram doses in the pregnant population.
引用
- Gillespie CD, Yates A, Hughes M, et al. Validating the safety of low-dose CTPA in pregnancy: results from the OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) Study. Eur Radiol. 2024. PMID: 38296849. doi:10.1007/s00330-024-10593-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。